ULTIVA Post Marketing Surveillance

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Analgesia

Treatments: Drug: Remifentanil

Study type: Observational

Funder types: Industry

Identifiers

NCT01299584

105936

Details and patient eligibility

About

This study is a post-marketing surveillance to monitor safety and efficacy of remifentanil during various surgeries and identify SAEs, adverse drug reactions, and unexpected AEs not described as precautions or warnings and to identify prognostic factors that have an effect on the AEs and to assess effectiveness of remifentanil in real clinical practices after marketing.

The subjects are patients prescribed for remifentanil by the investigators at the sites based on prescription information in normal clinical practices.

Enrollment: 775 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients requiring general anesthesia

Exclusion criteria

• According to precautions or warnings on PI, remifentanil should not be administered to the following patients
• Patients with any allergic reaction to any ingredients of remifentanil or other fentanyl analogues

Trial design

775 participants in 1 patient group

Remifentanil

Description:

Patients administrated remifentanil at the site

Treatment:

Drug: Remifentanil